Tetraphase Pharmaceuticals, Inc. (TTPH) Receives “Hold” Rating from Needham & Company LLC
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH)‘s stock had its “hold” rating restated by stock analysts at Needham & Company LLC in a research note issued to investors on Sunday.
Other equities analysts have also issued research reports about the stock. Stifel Nicolaus raised shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and increased their price target for the stock from $8.00 to $15.00 in a report on Wednesday, July 26th. HC Wainwright assumed coverage on shares of Tetraphase Pharmaceuticals in a report on Tuesday, July 11th. They set a “buy” rating and a $15.00 target price on the stock. Zacks Investment Research lowered shares of Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 30th. BMO Capital Markets reaffirmed an “outperform” rating and set a $13.00 target price (up previously from $12.00) on shares of Tetraphase Pharmaceuticals in a report on Wednesday, July 26th. Finally, BidaskClub raised shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 22nd. One analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company’s stock. Tetraphase Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $10.88.
Tetraphase Pharmaceuticals (NASDAQ TTPH) opened at 6.94 on Friday. The company’s market capitalization is $354.31 million. The company has a 50-day moving average of $6.28 and a 200-day moving average of $7.27. Tetraphase Pharmaceuticals has a 52 week low of $3.11 and a 52 week high of $9.93.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.76) by ($0.07). The company had revenue of $1.59 million during the quarter, compared to the consensus estimate of $1.54 million. Tetraphase Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 2,092.20%. Tetraphase Pharmaceuticals’s quarterly revenue was up 28.2% on a year-over-year basis. During the same period in the previous year, the company earned ($0.47) EPS. On average, equities research analysts anticipate that Tetraphase Pharmaceuticals will post ($2.54) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This report was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/09/17/tetraphase-pharmaceuticals-inc-ttph-receives-hold-rating-from-needham-company-llc.html.
In related news, insider Jacques Dumas sold 17,500 shares of the stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $6.00, for a total value of $105,000.00. Following the completion of the transaction, the insider now directly owns 17,500 shares in the company, valued at approximately $105,000. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 5.50% of the company’s stock.
Institutional investors have recently modified their holdings of the stock. Teza Capital Management LLC increased its stake in shares of Tetraphase Pharmaceuticals by 8.9% in the 1st quarter. Teza Capital Management LLC now owns 15,650 shares of the biopharmaceutical company’s stock worth $144,000 after acquiring an additional 1,281 shares in the last quarter. Citadel Advisors LLC increased its stake in shares of Tetraphase Pharmaceuticals by 18.6% in the 1st quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock worth $146,000 after acquiring an additional 2,496 shares in the last quarter. UBS Group AG increased its stake in shares of Tetraphase Pharmaceuticals by 2.3% in the 1st quarter. UBS Group AG now owns 17,269 shares of the biopharmaceutical company’s stock worth $159,000 after acquiring an additional 387 shares in the last quarter. AXA bought a new position in shares of Tetraphase Pharmaceuticals in the 2nd quarter worth about $132,000. Finally, Jane Street Group LLC bought a new position in shares of Tetraphase Pharmaceuticals in the 1st quarter worth about $181,000. Institutional investors own 41.73% of the company’s stock.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Stock Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.